Evidence map›Paper›PMID 27448305›Full record

ArticleTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2016

CYLD downregulates Livin and synergistically improves gemcitabine chemosensitivity and decreases migratory/invasive potential in bladder cancer: the effect is autophagy-associated.

Lei Yin, Shuai Liu, Chensheng Li, Sentai Ding, Dongbin Bi, Zhihong Niu, Liping Han, Wenjia Li, Dexuan Gao, Zheng Liu and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Lei YinDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jingwu Road, No 324, Jinan, 250021, Shandong, China.
Shuai LiuDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jingwu Road, No 324, Jinan, 250021, Shandong, China.
Chensheng LiDepartment of Digestive Diseases, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, 250021, China.
Sentai DingDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jingwu Road, No 324, Jinan, 250021, Shandong, China.
Dongbin BiDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jingwu Road, No 324, Jinan, 250021, Shandong, China.
Zhihong NiuDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jingwu Road, No 324, Jinan, 250021, Shandong, China.
Liping HanDepartment of Neurology, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan, 250014, China.
Wenjia LiShandong University, Jinan, 250000, China.
Dexuan GaoDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jingwu Road, No 324, Jinan, 250021, Shandong, China.
Zheng LiuDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jingwu Road, No 324, Jinan, 250021, Shandong, China.
Jiaju LuDepartment of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jingwu Road, No 324, Jinan, 250021, Shandong, China. kyoto2310@sina.com.
Shandong Provincial Hospital · CNShandong University · CNShandong Provincial QianFoShan Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although GC (gemcitabine and cisplatin) chemotherapy remains an effective method for treating bladder cancer (BCa), chemoresistance is a major obstacle in chemotherapy. In this study, we determined whether gemcitabine resistance correlates with migratory/invasive potential in BCa and whether this relationship is regulated by the cylindromatosis (CYLD)-Livin module. First, we independently investigated the correlation of CYLD/Livin and gemcitabine resistance with the potential for tumor migration and invasiveness. Second, we found that co-transfected CYLD and Livin dramatically improved sensitivity to gemcitabine chemotherapy and decreased migration/invasion potential. Next, we determined that CYLD may regulate Livin by the NF-κB-dependent pathway. We also found that CYLD overexpression and Livin knockdown might improve gemcitabine chemosensitivity by decreasing autophagy and increasing apoptosis in BCa cells. Finally, the effects of CYLD-Livin on tumor growth in vivo were evaluated. Our study demonstrates that CYLD-Livin might represent a potential therapeutic for chemoresistant BCa.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsAntimetabolites, AntineoplasticApoptosisAutophagyBlotting, WesternCell Line, TumorCell MovementCell SurvivalDeoxycytidineDeubiquitinating Enzyme CYLDDown-RegulationDrug Resistance, NeoplasmFemaleGemcitabineGene Expression Regulation, NeoplasticAdaptor Proteins, Signal TransducingAntimetabolites, AntineoplasticBIRC7 protein, humanCYLD protein, humanDeoxycytidineDeubiquitinating Enzyme CYLDGemcitabineInhibitor of Apoptosis ProteinsNeoplasm ProteinsTumor Suppressor ProteinsAutophagyBladder cancer (BCa)Cylindromatosis (CYLD)GemcitabineLivin

Identifiers

PMID27448305
OpenAlexW2481290317

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.